<unk>  was approved by the U.S. Food and Drug Administration (FDA) in March 2017. It was approved by the European Medicines Agency (EMA) in August 2017. It was approved for use in the NHS by NICE in February 2021. It can be used in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers. In the clinical trial relevant for the drug's approval,<unk>  significantly improved progression-free survival (PFS), that is, the time span the cancer did not get worse. For patients receiving placebo plus letrozole, PFS was 16 months on average, while under<unk>  plus letrozole, PFS was 25 months as of the January 2017 analysis. The study is scheduled to run until September 2020.
Ribociclib
Palbociclib
Tamoxifen
Trastuzumab
Enzalutamide
N-Desmethyltamoxifen
Docetaxel
Bazedoxifene